Product Information
GABAPENTIN 250 MG/5 ML SOLN is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0876 per ML under NDC 59762505007. Its NADAC has been published 213 times since Sep 7, 2022.
FDA first approved this application on Mar 2, 2000. Its Orange Book therapeutic-equivalence code is AA.
Strength
250 mg/5mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762505007
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Authorized Generic (NDA)
FDA Application
NDA021129FDA Approved
3/2/2000
TE Code
AA
On Market Since
7/1/2022
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 250 MG/5 ML SOLN has been published 213 times since Sep 7, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0876 per ML |
|---|---|
| All-time high | $0.1379 (Sep 13, 2023) |
| All-time low | $0.0768 (Nov 20, 2024) |
| 52-week high | $0.0895 |
| 52-week low | $0.0825 |
| Median price | $0.0911 |
| Average price | $0.1002 |
| Largest weekly change | -23.5% (Apr 17, 2024) |
| Weeks tracked | 213 |
| Tracking since | Sep 7, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the gabapentin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 250 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 250 MG/5 ML SOLN, manufactured by Mylan Pharmaceuticals Inc., is $0.0876 per ML (NDC 59762505007), effective Sep 30, 2026.
How has the price of GABAPENTIN 250 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 250 MG/5 ML SOLN has held within roughly two percent of its current level. It has been tracked across 213 weekly CMS publications since Sep 7, 2022.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 250 MG/5 ML SOLN?
Since Sep 7, 2022, the NADAC for GABAPENTIN 250 MG/5 ML SOLN has ranged from a low of $0.0768 (Nov 20, 2024) to a high of $0.1379 (Sep 13, 2023), with a median of $0.0911 per ML.
Are there cheaper alternatives to GABAPENTIN 250 MG/5 ML SOLN?
No other NADAC-published product currently shares the active ingredient and strength of GABAPENTIN 250 MG/5 ML SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GABAPENTIN 250 MG/5 ML SOLN?
GABAPENTIN 250 MG/5 ML SOLN (NDC 59762505007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.